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New Hope Now for Bowed Tendons 

by Virginia B. Reef, D. VM. 
U ltrasonography is a well-established, valuable tool for diagnosing the 
type and severity of tendon and ligament 
injuries in horses. 
Its use as part of a rehabilitation pro­
gram can help the veterinarian, trainer 
and owner success fully return the horse 
to competition, minimizing the chances 
of the horse's returning successfully to 
its previous level of competition. 
Beta-aminoproprionitrile (BAPN) is a 
scar-remodeled drug which has been 
shown to improve the quality of tendon 
and ligament repair in horses. 
BAPN is found in seeds of the wild 
sweet pea, Lathyrus odoratus. BAPN, ad­
ministered in the early stages of sca r for­
mation , blocks the enzyme Iysyl oxidase 
and thus blocks the formation of col­
lagen cross-links in the area of injury. 
This brief interruption of collagen cross­
linking allows for physiologically benefi­
cial scar remodeling to occur. 
Clinical trials using beta­
aminoproprionitrile fumarate (BAPN-F) 
in horses with acute bowed tendons have 
demonstrated improved tendon healing. 
Carefully designed double-blind placebo 
controlled trials showed the efficacy of 
thi s treatment. These studies are an im­
pOltant new application of ultrasonogra­
phy and should help veterinary medicine 
make significant advances in the treat­
ment of tendon and ligament inj uries in 
horses. 
DOUble-blind placebo controlled trials 
have not previously been performed to 
eval uate the efficacy of other treatments 
for tendon and ligament injuries. 
More than 200 horses with a recent 
injury (one to three months) to the super­
ficial digital flexor tendon have been 
treated with intralesional BAPN-F 
(Alcoa Inc., Tucson, AZ) following the 
tendon injury, primalily at the University 
of Pennsylvania School of Veterinary 
Medicine at New Bolton Center in 
Kennett Square, PA by my coworkers 
and me, and at Randall Veterinary Hospi­
tal in Warrensville Heights, OH, by Dr. 
Ron Genovese and his coworkers. This 
drug has al so been administered to 
horses with other tendon and ligament 
InJuries. 
All horses were racing, 
training or involved in other 
types of equestrian competi­
tion at the time the injury oc­
curred. The majority of treated 
horses were racehorses. 
The treated horses had large areas of 
damage to the superficial digital flexor 
tendon. Affected tendons were at least 
50% larger than normal or the cross­
sectional area of the affected tendon was 
at least 1.5cm. The lesion involved at 
least 25% of the tendon's cross-sectional 
area at its worst and extended over at 
least three of seven zones. 
Following a sterile prep, BAPN-F was 
injected throughout the injured area with 
a 27 - gauge needle every other day for a 
total of five treatments. 
Horses were then placed in a rigorou s 
low-level controlled exercise program 
with frequent ultrasound monitoring. The 
treated horses began walking 30 minutes 
per day for four weeks, which then in­
creased to 45 minutes daily for another 
four week s. All subsequent increases in 
the horse's exercise were based upon im­
provement in the ultrasound 
(sonographic) findings. 
If sonographic improvement was de­
tected eight weeks following treatment, a 
small amount of jogging (no more than 
five minutes per day at a five to six 
minute per mile pace) or swimming exer­
cise was added to the exercise program. 
This was increased to 10 minutes per day 
if sonographic improvement was de­
tected at 12 weeks. 
If continued sonographic improve­
ment occurred at 16 weeks, then turnout 
in a small paddock was permitted. The 
amount of jogging exercise remained 
stable or continued to increase by five 
minutes per month until 24 weeks. 
If continued sonographic improve­
ment occurred at 24 weeks, the horses 
started galloping. The first start occurred 
no sooner than 40 weeks following treat­
ment and was longer in horses with more 
severe injuries. 
Follow-up ultrasound examinations 
revealed a better quality of tendon repair 
in the BAPN-F treated horses, when 
compared to placebo controls. 
Tendon cross-sectional area was sig­
nificantly decreased , and fiber alignment 
was improved significantly at 16 weeks 
in horses treated with the seven or eight­
mg doses of BAPN-F. These findings 
persi sted as the horse went on into more 
rigorous training. 
Any increase in tendon cross-sec­
tional area (thickening) between exami­
nations resulted in the horse remaining at 
the same exercise level for an additional 
four weeks, unless the increase in tendon 
cross-sectional area was greater than or 
equal to 25%, in which case the amount 
of trotting exercise was decreased or dis­
continued altogether for the subsequent 
four weeks. 
Increases in tendon cross-sectional 
area of thi s magnitude indicated exces­
si ve tendon loading for the stage tendon 
healing and increased the ri sk for re­
llljury. 
A gradually increasing controlled ex­
ercise program should be a routine part 
of the rehabilitation of horses with ten­
don and ligament injuries. 
Periodic ultrasound examinations 
should be performed prior to each in ­
crease in the horse 's exercise level to be 
sure that the horse is ready to advance to 
the next exercise level. 
Long-term follow-up data is still be­
ing obtained on these horses to evaluate 
their return to performance. But initial 
studies indicate a significantly high per­
centage of BAPN-F treated horses are 
able to return successfully to competition 
without recurrence of the injury, the ulti­
mate goal of the treatment of equine ath­
letes with tendon injuries . • 
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